Why the study?
Does blood pressure control with ACE inhibitors or ARBs reduce the progression of renal failure and cardiovascular morbidity in patients with kidney disease?
Population
Patients with renal failure and hypertension, including non-diabetic and diabetic nephropathies
Design
Review
Authors
Loading...
Supports ACEI/ARB use to slow CKD progression; leaves open optimal targets and combinations in advanced disease.
Does blood pressure control with ACE inhibitors or ARBs reduce the progression of renal failure and cardiovascular morbidity in patients with kidney disease?
Strict blood pressure control, particularly with ACE inhibitors or ARBs, is essential to slow the progression of renal failure and reduce associated cardiovascular morbidity and mortality.
J A Whitworth (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: